Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTG/3TC First-line With Optional Switch to CAB + RPV LA in ART-naïve Adults With HIV-1
2023-503893-19-00Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label trial of dolutegravir + lamivudine, cabotegravir and rilpivirine long-acting in Human immunodeficiency virus infection type 1 (2 arms), sponsored by ViiV Healthcare. Primary endpoints: Time to virologic suppression on DTG/3TC and Virologic suppression after 1 year on CAB + RPV LA. Started Nov 2023; status: completed.
02
Drugs
dolutegravir + lamivudinecabotegravirrilpivirine long-acting
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2023-503893-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503893-19-00.